Target intelligence / Profile preview

Metallothionein-3 (MT-3) (MT-3)

Target
MT-3
Molecular classification
Metallothionein family, Metal-binding protein, Cytosolic protein
01

Overview

Metallothionein-3 (MT-3), also known as Growth Inhibitory Factor (GIF), is a small, cysteine-rich, metal-binding protein primarily expressed in the central nervous system [1, 6, 8]. Unlike other members of the metallothionein family, MT-3 possesses a unique ability to inhibit neurite outgrowth and neuronal survival, a function attributed to specific structural motifs like the TCPCP sequence in its N-terminal domain [1, 7, 12]. It plays a critical role in maintaining zinc and copper homeostasis and acts as a potent antioxidant by scavenging reactive oxygen species [1, 10, 13]. In neurodegenerative conditions such as Alzheimer's disease, MT-3 levels are significantly reduced, leading to impaired metal regulation and increased oxidative stress [1, 10, 13]. Conversely, in certain cancers like hepatocellular carcinoma and acute myeloid leukemia, MT-3 expression is often dysregulated and can contribute to drug resistance or act as a tumor suppressor [15, 16]. Therapeutic strategies targeting MT-3 focus on modulating its metal-binding capacity or restoring its expression to mitigate neurodegeneration and improve treatment outcomes in oncology [1, 14, 16].

Other names
Growth inhibitory factorGIFGIFBMetallothionein-IIIMT-IIIMT3
02

Mechanism of action

Metal sequestration and release, reactive oxygen species scavenging, modulation of lysosomal pH, and interaction with cytoskeletal and signaling proteins [1, 12, 13, 14].

03

Biological functions

Zinc homeostasisCopper homeostasisInhibition of neurite outgrowthAntioxidant activityRegulation of apoptosisRegulation of autophagyRegulation of lysosomal function
04

Disease associations

Alzheimer's diseaseParkinson's diseaseAmyotrophic lateral sclerosisAcute myeloid leukemiaHepatocellular carcinomaBladder cancerProstate cancerNeuroblastomaOsteoporosisDiabetes
05

Safety considerations

Essential metal dyshomeostasisImpairment of neuronal regenerationPromotion of drug resistance in cancer
06

Interacting drugs

Zinc

7 more in the full profile.

07

Biomarkers

MT-3 protein levelsMT-3 mRNA expressionMT-3 promoter methylation status

Beyond the preview

Go deeper on Metallothionein-3 (MT-3) (MT-3).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Metallothionein-3 (MT-3) (MT-3).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call